<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317174</url>
  </required_header>
  <id_info>
    <org_study_id>759346/002</org_study_id>
    <nct_id>NCT00317174</nct_id>
  </id_info>
  <brief_title>A Study to Assess Antibody Persistence, Boostability &amp; Safety in Previously Primed Subjects.</brief_title>
  <official_title>Assess Immune Persistence &amp; Memory by Giving Plain PRP,PSA &amp; PSC (10 Mths Age), &amp; Immunogenicity &amp; Safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 Booster (15-18 Mths Age) in Previously Primed Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is as follows:

        -  To evaluate the persistence of antibodies and the presence of immune memory induced by a
           3-dose primary vaccination with Tritanrix™-HepB/Hib-MenAC (three formulations) in the
           study DTPwHB/HibMenACTT001 (CPMS No. 759346/001) by giving unconjugated PRP, PSA and PSC
           at 10 months age to one subset of subjects.

        -  To evaluate the persistence of all antibodies pertaining to primary vaccination and the
           booster response to Tritanrix™-HepB/Hib2.5 vaccine or Tritanrix™-HepB/Hib-MenAC vaccine
           at 15-18 months age in the other subset of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two stages:

      At 10 months age, half of the subjects will receive a dose of plain meningococcal AC and PRP
      polysaccharide (PS) vaccine at 10 months age.

      At 15 to 18 months age (DTP booster phase), all subjects will receive a booster dose of
      Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hib2.5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre &amp; 1M post-plain PS, antibody levels &amp; bactericidal titers (meningococcal serogroups A &amp; C). Pre &amp; 1M post-DTP booster, antibody levels for all vaccine antigens.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre &amp; 1M post-DTP booster (subset of subjects), antibody levels for all vaccine antigens. Retrospective serious adverse events (SAEs). Solicited (day 0-7), unsolicited events (day 0-30). SAEs (entire study)</measure>
  </secondary_outcome>
  <enrollment>450</enrollment>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Tetanus</condition>
  <condition>Whole Cell Pertussis</condition>
  <condition>Hepatitis B</condition>
  <condition>Diphtheria</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPw-HBV/Hib-MenAC conjugate vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        • Healthy child 10 months that participated in the study DTPwHB/HibMenACTT001 (CPMS No.
        759346/001), written informed consent obtained from the parents.

        Exclusion criteria:

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             during the period starting from 30 days before and ending 30 days after administration
             of study vaccines with the exception of oral polio vaccine (OPV).

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine, or planned
             use during study period.

          -  Chronic administration (&gt; 14 days) of immunosuppressants or other immune-modifying
             drugs within 6 months prior to the first vaccine dose.

          -  Previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis B,
             serogroups A or C meningococcal disease and/or Hib since the last visit of study
             759346/001.

          -  History of/known exposure to diphtheria, tetanus, pertussis, hepatitis B, serogroups A
             or C meningococcal and/or Hib disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis. 2008 May;12(3):278-88. Epub 2007 Nov 5.</citation>
    <PMID>17981067</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>April 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2006</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>759346/002</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>759346/002</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>759346/002</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>759346/002</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>759346/002</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>759346/002</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

